Autopsy report · NCT02125266

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

“Study terminated due to unacceptable frequency of drug related adverse events”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 11 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Forsight Vision4

Sponsor type

Industry

Conditions

Uveitis, Posterior; Uveitis, Intermediate

Interventions

V404

Participants

7

Sites

5

Countries

United States

Trials that died the same way

• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (80% match in meaning)
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
  “The study was terminated because we were not able to obtain the study drug.” (77% match in meaning)
• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
  “Study terminated due to toxicity” (77% match in meaning)
• One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
  “The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.” (75% match in meaning)
• Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
  “Study was terminated early due to lack of experimental medication (supply issues)” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.